Download PDF
Eur J Pediatr Surg 2019; 29(05): 401-407
DOI: 10.1055/s-0038-1673708
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Comparison of Corticosteroid and Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted Angioma: A Systematic Review and Meta-Analysis

Wei Yao
1   Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, People's Republic of China
,
Kai Li
1   Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, People's Republic of China
,
Zuopeng Wang
1   Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, People's Republic of China
,
Jiahao Pei
1   Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, People's Republic of China
,
Xiangqi Liu
1   Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, People's Republic of China
,
Shan Zheng
1   Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, People's Republic of China
,
Kuiran Dong
1   Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, People's Republic of China
› Author Affiliations
Further Information

Publication History

06 June 2018

30 August 2018

Publication Date:
29 October 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Objective To evaluate the outcome and safety of corticosteroids and vincristine (VCR) in the treatment of kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

Materials and Methods Clinical studies involving corticosteroids and VCR therapies in treating KHE/TA were identified by using PubMed, Cochrane Library, OVID, EBSCO, CNKI, VIP, and Wanfang databases from their establishment date to December 2017. Randomized controlled trials, case–control, or case series with more than five cases were included. The following data were extracted: study sample, demographics, responses rate, recurrence rate, and adverse reactions. Two reviewers completed screening and extraction. Methodological quality was evaluated with quality appraisal tool.

Results A total of 266 studies were found, and 27 studies were finally included in this research; quality of all studies was low. Seven studies with a total of 123 participants, which compared the effect of systemic corticosteroids with that of VCR, were performed for the meta-analysis. The results indicated that the effect of VCR was significantly higher than that of corticosteroids (relative risk [RR] = 2.08, 95% confidence interval [CI]: 1.38–3.16). The recurrence rate of VCR (11.1%) was lower than that of corticosteroids (50%), but there was no statistical difference between the two therapies (p = 0.1312). The result of pooled adverse reactions response rate for VCR was 18.2%, significantly lower than that for corticosteroids, which was 52.0%.

Conclusion The present profile shows that VCR is relatively more effective and safer in treating KHE/TA than corticosteroids are. So, we believe VCR could be used as a first-line medication agent in the treatment of KHE/TA.

Keywords

kaposiform hemangioendothelioma - tufted angioma - corticosteroids - vincristine - meta-analysis

Note

Informed consent was obtained from all individual participants included in the study.


 

  • Reference

  • 1 Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993; 17 (04) 321-328
    CrossrefPubMedGoogle Scholar
  • 2 Fernández Y, Bernabeu-Wittel M, García-Morillo JS. Kaposiform hemangioendothelioma. Eur J Intern Med 2009; 20 (02) 106-113
    CrossrefPubMedGoogle Scholar
  • 3 Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100 (06) 1377-1386
    CrossrefPubMedGoogle Scholar
  • 4 Drolet BA, Trenor III CC, Brandão LR. , et al. Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma. J Pediatr 2013; 163 (01) 285-291
    CrossrefPubMedGoogle Scholar
  • 5 Margolin JF, Soni HM, Pimpalwar S. Medical therapy for pediatric vascular anomalies. Semin Plast Surg 2014; 28 (02) 79-86
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Drucker AM, Pope E, Mahant S, Weinstein M. Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma. J Cutan Med Surg 2009; 13 (03) 155-159
    CrossrefPubMedGoogle Scholar
  • 7 Fahrtash F, McCahon E, Arbuckle S. Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine. J Pediatr Hematol Oncol 2010; 32 (06) 506-510
    CrossrefPubMedGoogle Scholar
  • 8 Moga C, Guo B, Schopflocher D. , et al. Development of a Quality Apraisal Tool for Case Series Studies Using a Modified Delphi Technique. Edmonton, Alberta: Institute of Health Economics; 2012
    PubMed
  • 9 Ryan C, Price V, John P. , et al. Kasabach-Merritt phenomenon: a single centre experience. Eur J Haematol 2010; 84 (02) 97-104
    CrossrefPubMedGoogle Scholar
  • 10 Yasui N, Koh K, Kato M. , et al. Kasabach-Merritt phenomenon: a report of 11 cases from a single institution. J Pediatr Hematol Oncol 2013; 35 (07) 554-558
    CrossrefPubMedGoogle Scholar
  • 11 Wang P, Zhou W, Tao L, Zhao N, Chen XW. Clinical analysis of Kasabach-Merritt syndrome in 17 neonates. BMC Pediatr 2014; 14: 146
    CrossrefPubMedGoogle Scholar
  • 12 Boccara O, Fraitag S, Lasne D. , et al. Kaposiform haemangioendothelioma-spectrum lesions with Kasabach-Merritt phenomenon: retrospective analysis and long-term outcome. Acta Derm Venereol 2016; 96 (01) 77-81
    PubMedGoogle Scholar
  • 13 Yuan SM, Shen WM, Wang X. , et al. Clinical study on 11 cases of Kasabach-Merritt phenomenon in Chinese children. J Tissue Eng and Reconstr Surg 2010; 6 (03) 148-152
    PubMedGoogle Scholar
  • 14 Miao X, Tianxiang O, Yan X. , et al. [Comprehensive therapy for infant vascular tumor associated with Kasabach-Merritt phenomenon]. Zhonghua Zheng Xing Wai Ke Za Zhi 2015; 31 (04) 263-268
    PubMedGoogle Scholar
  • 15 Sun YC, Li K, Zheng S. , et al. The initial experience of treatment of Kasabach-Merritt syndrome with vincristine. Linchuang Xiaoer Waike Zazhi 2009; 8 (05) 3-5
    PubMedGoogle Scholar
  • 16 Haisley-Royster C, Enjolras O, Frieden IJ. , et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24 (06) 459-462
    CrossrefPubMedGoogle Scholar
  • 17 Rodriguez V, Lee A, Witman PM, Anderson PA. Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol 2009; 31 (07) 522-526
    CrossrefPubMedGoogle Scholar
  • 18 Larsen EC, Zinkham WH, Eggleston JC, Zitelli BJ. Kasabach-Merritt syndrome: therapeutic considerations. Pediatrics 1987; 79 (06) 971-980
    PubMedGoogle Scholar
  • 19 Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, Bernabeu-Wittel J, Ramirez-Villar GL. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2013; 60 (09) 1478-1481
    CrossrefPubMedGoogle Scholar
  • 20 Shin HY, Ryu KH, Ahn HS. Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome. Pediatr Int 2000; 42 (06) 620-624
    CrossrefPubMedGoogle Scholar
  • 21 Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer 2015; 62 (04) 577-580
    CrossrefPubMedGoogle Scholar
  • 22 Wananukul S, Nuchprayoon I, Seksarn P. Treatment of Kasabach-Merritt syndrome: a stepwise regimen of prednisolone, dipyridamole, and interferon. Int J Dermatol 2003; 42 (09) 741-748
    CrossrefPubMedGoogle Scholar
  • 23 Tan XY, Zhang J, Zhou SY. , et al. Successful treatment of steroid-resistant Kasabach-Merritt syndrome in infants with transcatheter arterial scleroembolization and vincristine. Zhonghua Fang She Xue Za Zhi 2014; 48 (11) 934-937
    PubMedGoogle Scholar
  • 24 Xia HP, He ZJ, Zhu JX. , et al. Kasabach-Merritt syndrome:report of ten cases. Zhongguo Shiyong Erke Zazhi 2011; 26 (02) 125-127
    PubMedGoogle Scholar
  • 25 Zhang YY, Zhang YH, Luo J, Xiang X. Kasabach-Merritt syndrome: eleven cases report. J China Pediatr Blood and Cancer. 2007; 12 (02) 64-67
    PubMedGoogle Scholar
  • 26 Jiang HX, Liu Y, Gao XM. Kasabach-Merritt syndrome: ten cases report. J Hainan Med. 2004; 15 (08) 104
    PubMedGoogle Scholar
  • 27 Qiu H. The treatment of Kasabach-Merritt syndrome: ten cases report. J Fujian Med. 2001; 23 (04) 93-94
    PubMedGoogle Scholar
  • 28 Li KL, Qin ZP, Liu XJ, Hu XQ. [Clinical analysis of 13 cases of hemangioma and vascular malformation associated with thrombopenia]. Shanghai Kou Qiang Yi Xue 2005; 14 (02) 108-112
    PubMedGoogle Scholar
  • 29 Qi HY, Ma L, Zhang JZ. Huge hemangioma combined with thrombocytopenia in infants: eight cases report. Linchuang Xiaoer Waike Zazhi 2008; 7 (06) 47-50
    PubMedGoogle Scholar
  • 30 Yan L, Xu Z, Sun YJ. , et al. Clinical analysis of 16 cases with infantile Kasabach-Merritt syndrome. J Pract Dermatol 2015; 8 (04) 257-259
    PubMedGoogle Scholar
  • 31 Lei HZ, Sun B, Liu DK. , et al. [Combined and sequential therapy for Kasabach-Merritt syndrome]. Zhonghua Yi Xue Za Zhi 2011; 91 (36) 2538-2541
    PubMedGoogle Scholar
  • 32 Wang X, Chen S, Qiao LJ. Clinical analysis of 5 cases of Kasabach-Merritt syndrome. J China Pediatr Blood and Cancer. 2014; 19 (06) 327-331
    PubMedGoogle Scholar
  • 33 Zhou B, Li WL, Shu Y. , et al. Clinical analysis on 13 cases with Kasabach-Merritt syndrome. Zhongguo Pifu Xingbingxue Zazhi 2009; 23 (04) 215-221
    PubMedGoogle Scholar
  • 34 Guo XK, Li P, Guo ZT. , et al. Retrospective analysis of 38 cases of Kasabach-Merritt syndrome. Zhongguo Pifu Xingbingxue Zazhi 2011; 25 (10) 775-777
    PubMedGoogle Scholar
  • 35 Hartman KR, Moncur JT, Minniti CP, Creamer KM. Mediastinal kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon. J Pediatr Hematol Oncol 2009; 31 (09) 690-692
    CrossrefPubMedGoogle Scholar
  • 36 Wang Z, Li K, Dong K, Xiao X, Zheng S. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2014; 61 (08) 1518-1519
    CrossrefPubMedGoogle Scholar
  • 37 Wang Z, Li K, Dong K, Xiao X, Zheng S. Successful treatment of Kasabach-Merritt phenomenon arising from kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 2015; 37 (01) 72-73
    CrossrefPubMedGoogle Scholar
  • 38 Garcia-Monaco R, Giachetti A, Peralta O. , et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns. J Vasc Interv Radiol 2012; 23 (03) 417-422
    CrossrefPubMedGoogle Scholar
  • 39 Malhotra Y, Yang CS, McNamara J, Antaya RJ. Congenital kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon successfully treated with low-dose radiation therapy. Pediatr Dermatol 2014; 31 (05) 595-598
    CrossrefPubMedGoogle Scholar
  • 40 Munn SE, Jackson JE, Jones RR. Tufted haemangioma responding to high-dose systemic steroids: a case report and review of the literature. Clin Exp Dermatol 1994; 19 (06) 511-514
    CrossrefPubMedGoogle Scholar